References
- DyerMJKelseySMMackayHJIn vivo purging of residual disease in CLL with Campath-1HBr J Haematol199797669729207420
- ElterTBorchmannPSchultzHFludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia results of phase II trialJ Clin Oncol20052370243116145065
- FaderlSThomasDAO’BrienSExperience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood20031013413512522009
- HillmenPSkotnickiARobakTPreliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) [abstract]J Clinc Oncol200624Suppl339s Abstract 6511
- HillmenPSkotnickiARobakTAlemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaJ Clin Oncol20072556162317984186
- KeatingMJFlinnIJainVTherapeutic role of alemtuzumab (Campath 1-H) in patients who have failed fludarabine: results of a large international studyBlood20029935546111986207
- KennedyBRawstronACarterCCampath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemiaBlood20029922454711877305
- LozanskiGHeeremaNAFlinnIWAlemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsBlood200410332788114726385
- LundinJKimbyEBjorkholmMPhase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath 1-H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Blood20021007687312130484
- MartinSIMartyFMFiumaraKInfectious complications associated with alemtuzumab use for lymphoproliferative disordersClin Infect Dis200643162416758413
- MontilloMTedeschiAAlemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemiaJ Clin Oncol20062423374216618945
- MontserratETreatment of chronic lymphocytic leukemia: achieving minimal residual disease negative status as a goalJ Clin Oncol2005232884515738532
- MoretonPKennedyBLucasGEradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survivalJ Clin Oncol20052329717915738539
- O’BrienSMKantarjianHMThomasDAAlemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaCancer20039826576314669286
- O’BrienKeatingMJMocarskiESUpdated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumabClin Lymphoma Myeloma200671253017026823
- OsterbergAFassasASAnagnosopoulosAHumanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukemiaBr J Haematol19969315138611450
- OsterborgADyerMJBunjesDPhase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemiaJ Clin Oncol1997151567749193354
- RaiKRByrdJCPetersonBSubcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 1990Blood2003 abstract 2506, 676a
- RaiKRByrdJCPetersonBLA phase II trial of fludarabine followed by alemtuzumab (Campath-1H in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease. Cancer and Leukemia Group B (CALG) Study 1 9901Blood2002a abstract 772, 205a
- RaiKRFreterCEMercierRJAlemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabineJ Clin Oncol2002b203891712228210
- RobakTDmosynskaAFetniRIncidence of genomic aberrations and associated efficacy from a phase III study alemtuzumab vs. chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (B-CLL)Blood2006108593a abstract 2092
- StilgenbauerSCohnerHCampath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapyN Engl J Med2002347452312167696
- WendtnerCMRitgenMSchweighofferCDConsolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLS)Leukemia200418109310115071604